Considerations for drug trials in hypertrophic cardiomyopathy

Considerations for drug trials in hypertrophic cardiomyopathy

Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies...

Full description

Saved in:
Bibliographic Details
Main Authors: John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:ESC Heart Failure
Subjects:
Hypertrophic cardiomyopathy
Clinical trials
Patient selection
Trial endpoints
Disease‐modifying therapy
Online Access:https://doi.org/10.1002/ehf2.15138
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.15138

Similar Items